Endogenous production of tumor necrosis factor in normal mice orally treated with deodan — A preparation from Lactobacillus bulgaricus “LB51”
Authors:
- Poly PopovaPPPoly Popova
- Guenka GuenchevaGGGuenka Guencheva
- Assen BogdanovABAssen Bogdanov
- Edoardo PacelliEPEdoardo Pacelli
- Alberto AuteriAAAlberto Auteri
- Verginia MinchevaVMVerginia Mincheva
- 1 November 1992
- journal article
- Published by Elsevier in International Journal of Immunopharmacology
- Vol. 14 (8) , 1355-1362
Abstract
No abstract availableKeywords
This publication has 16 references indexed in Scilit:
- Assay of Pyrogens by Interleukin-6 Release from Monocytic Cell LinesJournal of Pharmacy and Pharmacology, 1991
- Role of tumour necrosis factor in the tumour-necrotizing activity of agents with diverging toxicityCancer Immunology, Immunotherapy, 1991
- Phase I study of recombinant human tumor necrosis factor ? in advanced malignant diseaseCancer Immunology, Immunotherapy, 1989
- Molecular Transductional Mechanisms by which IFNγ and Other Signals Regulate Macrophage DevelopmentImmunological Reviews, 1987
- Polypetide mediator networkNature, 1987
- Tumour necrosis factor as immunomodulator and mediator of monocyte cytotoxicity induced by itself, γ-interferon and interleukin-1Nature, 1986
- Tumor Necrosis Factor (TNF)Science, 1985
- ANTI-TUMOUR THERAPY BY INDUCTION OF ENDOGENOUS TUMOUR NECROSIS FACTORThe Lancet, 1985
- Endotoxin-induced antitumor activity in the mouse is highly potentiated by muramyl dipeptideCancer Letters, 1984
- Antitumour glycopeptides from Lactobacillus bulgaricus cell wallFEBS Letters, 1975